Education
About Us
Working with TipRanks
Follow Us
HUTCHMED (HCM)
NASDAQ:HCM
HCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.51 - $21.50
Previous CloseN/A
Volume23.53K
Average Volume (3M)45.73K
Market Cap
$2.79B
Enterprise Value$1.37B
Total Cash (Recent Filing)$836.11M
Total Debt (Recent Filing)$89.82M
Price to Earnings (P/E)5.8
Beta0.25
Next Earnings
Feb 26, 2026EPS Estimate
2.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.60
Shares Outstanding174,422,290
10 Day Avg. Volume46,212
30 Day Avg. Volume45,727
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue2.18
Enterprise Value/Gross Profit19.81
Enterprise Value/Ebitda-43.72
Forecast
1Y Price Target
$21.25Price Target Upside35.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
HUTCHMED News
HCM FAQ
What was HUTCHMED’s price range in the past 12 months?
HUTCHMED lowest stock price was $11.51 and its highest was $21.50 in the past 12 months.
What is HUTCHMED’s market cap?
HUTCHMED’s market cap is $2.79B.
When is HUTCHMED’s upcoming earnings report date?
HUTCHMED’s upcoming earnings report date is Feb 26, 2026 which is in 182 days.
How were HUTCHMED’s earnings last quarter?
HUTCHMED released its earnings results on Aug 07, 2025. The company reported $2.6 earnings per share for the quarter, beating the consensus estimate of $1.457 by $1.143.
Is HUTCHMED overvalued?
According to Wall Street analysts HUTCHMED’s price is currently Undervalued.
Does HUTCHMED pay dividends?
HUTCHMED does not currently pay dividends.
What is HUTCHMED’s EPS estimate?
HUTCHMED’s EPS estimate is 2.5.
How many shares outstanding does HUTCHMED have?
HUTCHMED has 174,422,290 shares outstanding.
What happened to HUTCHMED’s price movement after its last earnings report?
HUTCHMED reported an EPS of $2.6 in its last earnings report, beating expectations of $1.457. Following the earnings report the stock price went down -8.984%.
Which hedge fund is a major shareholder of HUTCHMED?
Currently, no hedge funds are holding shares in HCM
HUTCHMED Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.25 (35.96% Upside)
$21.25 (35.96% Upside)
Blogger Sentiment
Bullish
HCM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 110.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.96%
12-Months-Change
Fundamentals
Return on Equity
47.53%
Trailing 12-Months
Asset Growth
40.85%
Trailing 12-Months
Company Description
HUTCHMED
HUTCHMED (HCM) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to address the unmet medical needs of patients, particularly in oncology and immunology. The company operates in the pharmaceutical sector and has a robust pipeline of drug candidates, with a strong emphasis on targeted therapies and immunotherapies for various types of cancer. HUTCHMED is committed to advancing its proprietary drug candidates and leveraging its partnerships to bring transformative treatments to market.
HCM Company Deck
HCM Earnings Call
Q2 2025
0:00 / 0:00
HCM Stock 12 Month Forecast
Average Price Target
$21.25
▲(35.96% Upside)
Technical Analysis
Dynavax
―
Perrigo Company
―
Supernus Pharmaceuticals
―
Amneal Pharmaceuticals
―
Alvotech
―
Ownership Overview
―
Insiders
0.05% Mutual Funds
0.58% Other Institutional Investors
99.27% Public Companies and
Individual Investors